Pharmacogenetic analysis of TS and UGT1A polymorphisms predictive for response and toxicity in Spanish patients with advanced colorectal cancer treated with first-line irinotecan and 5-fluorouracil

被引：0
|
作者：
Martinez-Balibrea, E. [1 ,2 ,3 ,4 ,5 ,6 ]
Abad, A. [1 ,2 ,3 ,4 ,5 ,6 ]
Valladares, M. [1 ,2 ,3 ,4 ,5 ,6 ]
Martinez-Villacampa, M. [1 ,2 ,3 ,4 ,5 ,6 ]
Aranda, E. [1 ,2 ,3 ,4 ,5 ,6 ]
Marcuello, E. [1 ,2 ,3 ,4 ,5 ,6 ]
Benavides, M. [1 ,2 ,3 ,4 ,5 ,6 ]
Martinez-Cardus, A. [1 ,2 ,3 ,4 ,5 ,6 ]
Gines, A. [1 ,2 ,3 ,4 ,5 ,6 ]
Manzano, J. L. [1 ,2 ,3 ,4 ,5 ,6 ]
机构：
[1] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Badalona, Spain
[2] Hosp Juan Canalejo, La Coruna, Spain
[3] Hosp Duran & Reynals, ICO, Lhospitalet De Llobregat, Spain
[4] Hosp Reina Sofia, Cordoba, Spain
[5] Hosp Sant Pau, Barcelona, Spain
[6] Hosp Carlos Haya, Malaga, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4066
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer
    von Weikersthal, Ludwig Fischer
    Schalhorn, Andreas
    Stauch, Martina
    Quietzsch, Detlef
    Maubach, Peter A.
    Lambertz, Helmut
    Oruzio, Daniel
    Schlag, Rudolf
    Weigang-Koehler, Karin
    Vehling-Kaiser, Ute
    Schulze, Manfred
    Truckenbrodt, Juergen
    Goebeler, Mariele
    Mittermueller, Johann
    Bosse, Daniel
    Szukics, Borika
    Grundeis, Marc
    Zwingers, Thomas
    Giessen, Clemens
    Heinemann, Volker
    EUROPEAN JOURNAL OF CANCER, 2011, 47 (02) : 206 - 214
  • [42] Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy (vol 99, pg 1050, 2008)
    Pare, L.
    Marcuello, E.
    Altes, A.
    del Rio, E.
    Sedano, L.
    Salazar, J.
    Cortes, A.
    Barnadas, A.
    Baiget, M.
    BRITISH JOURNAL OF CANCER, 2009, 100 (08) : 1368 - 1368
  • [43] Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin
    Han, Ji-Youn
    Lim, Hyeong-Seok
    Shin, Eun Soon
    Yoo, Yeon-Kyeong
    Park, Yong Hoon
    Lee, Jong-Eun
    Jang, In-Jin
    Lee, Doe Ho
    Lee, Jin Soo
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (15) : 2237 - 2244
  • [44] Irinotecan combined or alternated with bolus 5-fluorouracil and folinic acid versus the Mayo Clinic regimen in the first-line therapy of advanced colorectal cancer
    Graeven, U
    Ridwelski, K
    Artandi, M
    Espana, P
    Schölmerich, J
    Rosales, AM
    Carlsson, G
    Borner, M
    Boussard, B
    Schmiegel, W
    ONCOLOGY REPORTS, 2005, 13 (04) : 681 - 688
  • [45] Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy
    Ruzzo, Annamaria
    Graziano, Francesco
    Loupakis, Fotios
    Rulli, Eliana
    Canestrari, Emanuele
    Santini, Daniele
    Catalano, Vincenzo
    Ficarelli, Rita
    Maltese, Paolo
    Bisonni, Renato
    Masi, Gianluca
    Schiavon, Gaia
    Giordani, Paolo
    Giustini, Lucio
    Falcone, Alfredo
    Tonini, Giuseppe
    Silva, Rosarita
    Mattioli, Rodolfo
    Floriani, Irene
    Magnani, Mauro
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (10) : 1247 - 1254
  • [46] A potential predictive model for oxaliplatin plus 5-fluorouracil response in advanced colorectal cancer patients
    Gu, Junjie
    Li, Zhe
    Luo, Fei
    Zhou, Jianfeng
    Sun, Zhao
    Bai, Chunmei
    ANNALS OF ONCOLOGY, 2018, 29
  • [47] Combination chemotherapy with 5-fluorouracil and heptaplatin as first-line treatment in patients with advanced gastric cancer
    Min, YJ
    Bang, SJ
    Shin, JW
    Kim, DH
    Park, JH
    Kim, GY
    Ko, BK
    Choi, DH
    Cho, HR
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2004, 19 (03) : 369 - 373
  • [48] Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil
    Pfeiffer, P.
    Nielsen, D.
    Bjerregaard, J.
    Qvortrup, C.
    Yilmaz, M.
    Jensen, B.
    ANNALS OF ONCOLOGY, 2008, 19 (06) : 1141 - 1145
  • [49] Phase I/II trial of irinotecan plus high-dose 5-fluorouracil (TTD regimen) as first-line chemotherapy in advanced colorectal cancer
    Aranda, E
    Carrato, A
    Cervantes, A
    Sastre, J
    Gómez, MA
    Abad, A
    Masutti, B
    Ribera, F
    Marcuello, E
    Pronk, L
    Balcells, M
    Díaz-Rubio, E
    ANNALS OF ONCOLOGY, 2004, 15 (04) : 559 - 567
  • [50] 5-fluorouracil as a protracted continuous infusion plus irinotecan (CPT-11) in patients with advanced colorectal cancer treated with fluoropyrimidine-based regimens as first line
    Sastre, J
    Alfonso, R
    Macías, JA
    Manrique, I
    Flores, L
    Díaz-Rubio, E
    ANTI-CANCER DRUGS, 2003, 14 (07) : 543 - 547
12345